Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • A Study of MK-1084 Alone and Combined with Cetuximab for People with Advanced Solid Tumors that Have a KRAS G12C Gene Change

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Denmark France Germany Greece Italy Norway +3
  • Phase I/II study of DJI136 with drug combination in adult patients with extensive-stage small cell lung cancer

    Not yet recruiting

    2 1 1 1
    France Spain
  • A study to evaluate the safety and effectiveness of H-CYS(SS)-GLU-VAL-SER-GLN-LEU-LEU-LYS-GLY-ASP-ALA-CYS(SS)-OH in patients with advanced solid tumors who have completed other treatments.

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    Belgium France
  • A study to investigate the safety and effectiveness of WEF-001 in patients with advanced KRAS-mutant solid tumors

    Not yet recruiting

    1 1 1
    Investigated Drugs:
    Spain
  • Study of WEF-001 safety and effectiveness in patients with advanced KRAS-mutant solid tumors

    Not yet recruiting

    1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Spain
  • Study of Brentuximab Vedotin with Drug Combination for Untreated CD30-expressing Peripheral T-cell Lymphoma Patients

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    Czechia
  • Study of Propranolol and Vinorelbine for Children and Teenagers with Refractory or Relapsing Solid Tumors

    Not yet recruiting

    1 1 1 1
    France
  • Study on the Effectiveness and Safety of Luveltamab Tazevibulin Compared to Chemotherapy in Women with Relapsed Platinum-resistant Ovarian Cancer

    Not yet recruiting

    2 1 1 1
    Austria Belgium Czechia Finland Germany Hungary +3
  • Study of BLU-451 for Patients with Advanced Cancers Having EGFR Exon20 Insertion Mutations

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    Spain
  • A Study of CLDN6 CAR-T Cell Therapy With or Without CLDN6 RNA-LPX Vaccine in Patients With CLDN6-Positive Advanced Solid Tumors That Returned or Did Not Respond to Treatment

    Not recruiting

    1 1 1
    Germany The Netherlands Sweden